SCHEMBL5452943

SCHEMBL5452943

C=CCNc1c(N)c(Cl)nc2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.48
ALDH1A1 P00352 5/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
HPGD P15428 3/20 0.48
RAB9A P51151 6/20 0.47
KMT2A Q03164 7/20 0.44
MEN1 O00255 4/20 0.44
MAPT P10636 3/20 0.44
GAA P10253 3/20 0.44
GLA P06280 4/20 0.43
HSD17B10 Q99714 3/20 0.43
TSHR P16473 2/20 0.43
NPY1R P25929 1/20 0.43
SUMO3 P55854 1/20 0.42
SUMO2 P61956 1/20 0.42
SUMO1 P63165 1/20 0.42
PDE4B Q07343 1/20 0.40
PDE4D Q08499 1/20 0.40
HIF1A Q16665 2/20 0.40
POLB P06746 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL560210 0.81 POLB (0.58) KDM4EALDH1A1SMN1; SMN2HPGDRAB9A
SCHEMBL13968056 0.79 KMT2A (0.66) KDM4EALDH1A1SMN1; SMN2HPGDKMT2A
SCHEMBL12744366 0.78 APP (0.55) KDM4EALDH1A1RAB9AKMT2AMEN1
SCHEMBL14589446 0.78 ALDH1A1 (0.38) KDM4EALDH1A1SMN1; SMN2HPGDRAB9A
SCHEMBL8597992 0.78 KDM4E (0.45) KDM4EALDH1A1SMN1; SMN2RAB9AKMT2A
SCHEMBL1457240 0.78 KDM4E (0.45) KDM4EALDH1A1SMN1; SMN2HPGDRAB9A
SCHEMBL843109 0.77 KDM4E (0.49) KDM4EALDH1A1SMN1; SMN2HPGDRAB9A
SCHEMBL1456601 0.77 ACHE (0.53) KDM4EALDH1A1SMN1; SMN2HPGDRAB9A
SCHEMBL31197385 0.77 KDM4E (0.49) KDM4EALDH1A1SMN1; SMN2HPGDRAB9A
SCHEMBL22181050 0.76 ACHE (0.55) RAB9AKMT2APOLBRAD52ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070259881-A1 Substituted Imidazo Ring Systems and Methods COLEY PHARMACEUTICAL GROUP, INC. 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259881-A1 Substituted Imidazo Ring Systems and Methods IL2, IL4, IRF3 KDM4E 3339/4885ALDH1A1 2134/4885SMN1; SMN2 3807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.